Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines.
1/5 보강
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of just 7%.
APA
Hussain A, Fareed A (2025). Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines.. Journal, genetic engineering & biotechnology, 23(1), 100469. https://doi.org/10.1016/j.jgeb.2025.100469
MLA
Hussain A, et al.. "Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines.." Journal, genetic engineering & biotechnology, vol. 23, no. 1, 2025, pp. 100469.
PMID
40074443 ↗
Abstract 한글 요약
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of just 7%. Its late diagnosis and limited treatment options contribute to poor outcomes. Immunotherapy has had little success due to PDAC's dense and immunosuppressive tumor environment. Emerging mRNA vaccines, such as autogene cevumeran (BNT122), show promise in enhancing treatment. Preliminary trials have reported prolonged survival with minimal side effects. Despite this progress, the complexity of PDAC remains a significant challenge. Continued research is essential to fully realize the potential of mRNA-based therapies in combating this deadly cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Shared Plasma Fatty Acid Profiles in Four Cancer Types Enable Diagnosis and Discrimination of Gastrointestinal and Lung Cancers.
- Smooth muscle cells from skin perforator vessels as a new tool for vascular research.
- Marine life as a source of anti-prostate cancer agents: an updated overview (2003-2023).
- A New Ultrasound-Guided, One-Point, Single Interfascial Plane Botulinum Toxin A Injection Technique for the Repair of Ventral Abdominal Wall Hernias Before Surgery: A Case Report.
- Maximizing the Virtual Patient Encounter in Oculofacial Plastic Surgery.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24).